全部

1·OBJECTIVE: to preparation loratadine tablets and to establish a methods of quality for it.

目的：制备氯雷他定片并建立其质量控制方法。

2·Results Arachidonic acid-induced ear edema was reduced by mizolastine, but loratadine and cetirizine were not.

结果咪唑斯汀可抑制花生四烯酸诱导的小鼠耳部水肿，但氯雷他定和西替利嗪均不能；

3·Efficacy and Safety of Mizolastine Sustained Release Tablets Comparison with Loratadine Tablets in Patients with Urticaria;

目的比较咪唑斯汀缓释片与氯雷他定片治疗荨麻疹的有效性与安全性。

4·Aim To study the pharmacokinetics and relative bioavailability of domestic loratadine capsules and tablets in healthy volunteers.

目的研究氯雷他定胶囊与片剂的人体药动学和生物等效性。

5·Objective To evaluate the clinical effectiveness and safety of compound loratadine capsule in the treatment of allergic rhinitis.

目的评价复方氯雷他定缓释胶囊治疗变应性鼻炎的有效性和安全性。

6·Conclusion Loratadine and ketotifen can inhibit the exercise-induced bronchoconstriction in guinea pigs pretreated with LPS and metyrapone.

结论在用脂多糖和甲吡丙酮预处理的运动性哮喘豚鼠模型中，氯雷他定和酮替芬能够抑制支气管收缩。

7·Methods 82 patients were randomly divided into 2 groups and treated with loratadine and ranitidine or a combination of glycyrrhizin separately.

方法82例慢性荨麻疹患者随机分为治疗组和对照组，对照组予氯雷他定口服及雷尼替丁静脉滴注，1周后改为口服。

8·Results the total effective rate was 87.93% for azelastine group and 82.54% for loratadine group, and the adverse event rate was 8.62% and 14.06%, respectively.

结果盐酸氮革斯汀片和氯雷他定片治疗变应性鼻炎的有效率分别为87.93%，82.54%；药物不良反应发生率分别为8.62%，14.06%。

9·OBJECTIVE: To compare the antihistamine activity of desloratadine, the active metabolite of loratadine, with that of cetirizine in the skin wheal-and-flare responses during 24 hours.

目的：比较地氯雷他定(氯雷他定的活性代谢产物)与西替立嗪在24小时内对皮肤风团及潮红应答的治疗效果。

10·Method 140 cases of AR were randomly divided into two group. 68 cases of observed group (OG) were treated with microwave heat coagulation. 72 cases of control group (CG) took orally loratadine tablet.

方法将14 0例变应性鼻炎随机分为两组，观察组6 8例施以微波选择性多点热凝治疗，对照组72例服用抗组胺药物氯雷他定治疗。

氯雷他定

1·Aim To study the pharmacokinetics and relative bioavailability of domestic loratadine capsules and tablets in healthy volunteers.

目的研究氯雷他定胶囊与片剂的人体药动学和生物等效性。